The vaccine has the potential to significantly lower the number of deaths caused by the disease, according a the study published in the journal Science Advances.
In 2004, pneumonia killed more than two million children worldwide, according to the World Health Organization (WHO), by 2015, the number was less than one million.
The new vaccine, which is under development provoked an immune response to 72 forms of S pneumoniae - including the 23 mentioned above - in lab tests on animals.
Key to the technology is a liposome - a tiny liquid- filled bubble made of fat - that acts as a storage tank for the sugars, they said.
Since the sugars are not covalently bonded, it is possible that the liposome could host all of the sugars that identify individual strains of S pneumoniae, researchers said.
"We have made tremendous progress fighting the spread of pneumonia, especially among children. However, if we are ever going to rid ourselves of the disease, we need to create smarter and more cost-effective vaccines," said Blaine Pfeifer associate professor at the University at Buffalo in the US.
The team added proteins at the surface of the liposome which, together with the sugars, provoke immunotherapy.
Researchers performed tests on mice and rabbits, and noted that the new vaccine stimulated an immune response to 72 of the more than 90 known strains of S pneumoniae.
"We now have the ability to watch over bacteria and attack it only if it breaks away from the colony to cause an illness," said Charles H Jones, from University of Buffalo.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
